Immune responses to zoster vaccines

Immune responses to zoster vaccines

There are two licensed herpes zoster vaccines. One is a live vaccine (ZVL) based on an attenuated varicella-zoster virus (VZV). The other is a recombinant vaccine (RZV) based on the VZV glycoprotein E (gE) combined with AS01B, a multicomponent adjuvant system. RZV is superior to ZVL in efficacy, and...

Full description

Bibliographic Details
Main Authors:	Myron J Levin, Adriana Weinberg
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2019-04-01
Series:	Human Vaccines & Immunotherapeutics
Subjects:	herpes zoster older adults immune responses zoster vaccine live recombinant zoster vaccine adjuvants vaccinology viral
Online Access:	http://dx.doi.org/10.1080/21645515.2018.1560918

Similar Items

Herpes zoster vaccination. An update
by: Khairuddin Djawad, et al.
Published: (2022-03-01)

Studies with herpes zoster vaccines in immune compromised patients
by: Myron J. Levin, et al.
Published: (2017-12-01)

Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review
by: Nikolaos Giannelos, et al.
Published: (2023-01-01)

Evaluation of two frailty indices, with practical application in a vaccine clinical trial
by: Desmond Curran, et al.
Published: (2019-12-01)

Prevention of Herpes Zoster: A Focus on the Effectiveness and Safety of Herpes Zoster Vaccines
by: Yasmin Marra, et al.
Published: (2022-11-01)

Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States who have been previously vaccinated with zoster vaccine live
by: Desmond Curran, et al.
Published: (2019-04-01)

Early impact of the Australian national shingles vaccination program with the herpes zoster live attenuated vaccine
by: John Litt, et al.
Published: (2020-12-01)

Knowledge, Attitudes and Practices Survey of Recombinant Zoster Vaccine among Cardiologists and Cardiac Nurses in Italy
by: Domenico Ponticelli, et al.
Published: (2024-01-01)

Real-world effectiveness of recombinant zoster vaccine in self-identified Chinese individuals aged ≥50 years in the United States
by: Ana Florea, et al.
Published: (2024-12-01)

Proceedings of the expert consensus group meeting on herpes zoster disease burden and prevention in India: An opinion paper
by: V Ramasubramanian, et al.
Published: (2023-08-01)

The Association between Varicella Vaccination and Herpes Zoster in Children: A Semi-National Retrospective Study
by: Ester Forer, et al.
Published: (2023-06-01)

Reactivation of Herpes Zoster Keratitis Following Shingrix Vaccine
by: Tracy J. Lu, et al.
Published: (2022-02-01)

Vacina contra herpes-zóster
by: Jacyr Pasternak

Projected risks and health benefits of vaccination against herpes zoster and related complications in US adults
by: Cara B. Janusz, et al.
Published: (2022-11-01)

Incidence of varicella and herpes zoster after inclusion of varicella vaccine in national immunization schedule in Turkey: time trend study
by: Ahmet Soysal, et al.
Published: (2021-03-01)

Varicella zoster virus vaccines: an update
by: Gabutti G, et al.
Published: (2019-08-01)

Low willingness to vaccinate against herpes zoster in a Chinese metropolis
by: Xinyue Lu, et al.
Published: (2021-11-01)

Herpes Zoster and Immunogenicity and Safety of Zoster Vaccines in Transplant Patients: A Narrative Review of the Literature
by: Lei Wang, et al.
Published: (2018-07-01)

Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults
by: Tino F. Schwarz, et al.
Published: (2018-06-01)

Public health impact of herpes zoster vaccination on older adults in Hong Kong
by: Paul K. S. Chan, et al.
Published: (2023-01-01)

The landscape of herpes zoster management and prevention in the Philippines: Proceedings from two advisory boards
by: Mario Panaligan, et al.
Published: (2023-08-01)

Immune response to the recombinant herpes zoster vaccine in people living with HIV over 50 years of age compared to non-HIV age-/gender-matched controls (SHINGR’HIV): a multicenter, international, non-randomized clinical trial study protocol
by: Maxime Hentzien, et al.
Published: (2024-03-01)

The review gives data on the clinical manifestations, complications, and epidemiological characteristics of herpes zoster.
by: N M Afonina, et al.
Published: (2013-11-01)

Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults ≥ 50 years of age with a prior history of herpes zoster: A phase III, non-randomized, open-label clinical trial
by: Olivier Godeaux, et al.
Published: (2017-05-01)

The adjuvanted recombinant zoster vaccine is efficacious and safe in Asian adults ≥ 50 years of age: a sub-cohort analysis of the ZOE-50 and ZOE-70 randomized trials
by: Joon Hyung Kim, et al.
Published: (2021-07-01)

Early examination of real-world uptake and second-dose completion of recombinant zoster vaccine in the United States from October 2017 to September 2019
by: Brandon J. Patterson, et al.
Published: (2021-08-01)

Attitudes, barriers, and facilitators to adherent completion of the recombinant zoster vaccine regimen in Canada: Qualitative interviews with healthcare providers and patients
by: Sydney George, et al.
Published: (2024-12-01)

Disseminated herpes zoster with cauda equina symptoms
by: Corey J. Steinberg, et al.
Published: (2020-01-01)

Willingness to accept herpes zoster vaccines and the influencing factors in China
by: Binshan Jiang, et al.
Published: (2022-11-01)

The impact of childhood varicella vaccination on the incidence of herpes zoster in the general population: modelling the effect of exogenous and endogenous varicella-zoster virus immunity boosting
by: Christophe Sauboin, et al.
Published: (2019-02-01)

Modeled impact of the COVID-19 pandemic and associated reduction in adult vaccinations on herpes zoster in the United States
by: Desmond Curran, et al.
Published: (2022-01-01)

Efficacy, effectiveness, and safety of herpes zoster vaccine in the immunocompetent and immunocompromised subjects: A systematic review and network meta-analysis
by: Yue Xia, et al.
Published: (2022-09-01)

Effect of Routine Varicella Immunization on the Epidemiology and Immunogenicity of Varicella and Shingles
by: Naruhito Otani, et al.
Published: (2022-03-01)

The potential public health impact of Herpes Zoster vaccination in the 65 years of age cohort in Italy
by: Antonio Volpi, et al.
Published: (2020-02-01)

Preclinical immunogenicity of an adenovirus-vectored vaccine for herpes zoster
by: Marta Ulaszewska, et al.
Published: (2023-01-01)

Acute retinal necrosis following recombinant subunit varicella-zoster virus vaccine
by: Rebecca I. Chen, et al.
Published: (2020-12-01)

Association of asthma and herpes zoster, the role of vaccination: A literature review
by: Abhigan Babu Shrestha, et al.
Published: (2022-11-01)

Herpes Zoster Ophthalmicus: A Devastating Disease Coming Back with Vengeance or Finding Its Nemesis?
by: Michael Tsatsos, et al.
Published: (2022-01-01)

Herpes zoster after inactivated COVID-19 vaccination
by: Vincent Ongko Wijaya, et al.
Published: (2022-01-01)

Recombinant Zoster Vaccine (Shingrix): a nex gun for Rheumatologist
by: D. Marotto, et al.
Published: (2022-03-01)